1. Home
  2. PARK vs BMEA Comparison

PARK vs BMEA Comparison

Compare PARK & BMEA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Park Dental Partners Inc.

PARK

Park Dental Partners Inc.

HOLD

Current Price

$19.80

Market Cap

94.5M

Sector

Health Care

ML Signal

HOLD

Logo Biomea Fusion Inc.

BMEA

Biomea Fusion Inc.

HOLD

Current Price

$0.70

Market Cap

92.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PARK
BMEA
Founded
1972
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Misc Health and Biotechnology Services
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.5M
92.1M
IPO Year
2025
2021

Fundamental Metrics

Financial Performance
Metric
PARK
BMEA
Price
$19.80
$0.70
Analyst Decision
Strong Buy
Buy
Analyst Count
2
8
Target Price
★ $28.50
$6.57
AVG Volume (30 Days)
27.5K
★ 2.4M
Earning Date
11-08-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ 69.19
EPS
★ 0.16
N/A
Revenue
N/A
N/A
Revenue This Year
$5.58
N/A
Revenue Next Year
$15.70
N/A
P/E Ratio
$121.44
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$11.39
$0.74
52 Week High
$26.79
$2.24

Technical Indicators

Market Signals
Indicator
PARK
BMEA
Relative Strength Index (RSI) 48.24 24.15
Support Level $18.99 N/A
Resistance Level $21.41 $1.47
Average True Range (ATR) 1.09 0.11
MACD -0.04 -0.06
Stochastic Oscillator 47.14 1.79

Price Performance

Historical Comparison
PARK
BMEA

About PARK Park Dental Partners Inc.

Park Dental Partners Inc is a dental resource organization (DRO) operating through its subsidiary. It Provides comprehensive business support services including clinical team members, administrative personnel, facilities and equipment to its affiliated general and multi-specialty dental practices throughout Minnesota and Wisconsin. Its network of affiliated dental practices provides both general and specialty dental services, including oral surgery, periodontics, pediatric dentistry, prosthodontics, endodontics, and orthodontics, under long-term agreements with initial terms of 30-years, with automatic 5-year renewals.

About BMEA Biomea Fusion Inc.

Biomea Fusion Inc is a a clinical stage diabetes and obesity medicines company focused on the discovery and development of oral, small molecule drugs to treat and improve the lives of patients with diabetes, obesity, and other metabolic diseases. It operate as an organization centered on two of its core drug candidate development programs: (i) icovamenib, its clinical program's drug candidate, currently being developed as an orally bioavailable, and selective, covalent inhibitor of menin in two clinical and multiple preclinical studies, investigating icovamenib's potential in type 1 and type 2 diabetes, as well as its impact in obesity, and (ii) BMF-650, its investigational, next-generation oral glucagon-like peptide-1 GLP-1 receptor agonist in development for the treatment of obesity.

Share on Social Networks: